Enhancement of human polymorphonuclear leukocyte adherence by the phospholipid mediator 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC).
The phospholipid mediator 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC) increases human polymorphonuclear leukocyte (PMN) adherence to Sephadex G-25 in manner directly proportional to the concentration of AGEPC from 2 to 650 nM. The maximal enhancement of PMN adherence of 85% +/- 23% (mean +/- SD) evoked by 650 nM AGEPC was indistinguishable in magnitude from that elicited by an optimal concentration of the chemotactic peptide N-f-Met-Leu-Phe. The results of analyses of the relative PMN adherence-enhancing activities of analogs of AGEPC suggest distinct molecular requirements for the enhancement of adherence. PMN adherence increases within 1 minute after exposure of the leukocytes to AGEPC, and the augmented adherence persists for over 30 minutes in spite of extensive washing of the leukocytes. Indomethacin partially blocked enhancement of adherence by AGEPC, suggesting that thromboxane A2 mediates in part the enhancement of adherence by AGEPC.[1]References
- Enhancement of human polymorphonuclear leukocyte adherence by the phospholipid mediator 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC). Valone, F.H., Goetzl, E.J. Am. J. Pathol. (1983) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
